China’s vaccine map: Efficacy of Sinopharm’s COVID-19 vaccines proved again in new trials

Two coronavirus vaccines developed by China’s Sinopharm have shown an efficacy of over 72 percent in phase-3 clinical trials, according to a study published in The Journal of the American Medical Association in May.

The two inactivated vaccines, developed by Sinopharm’s Wuhan Institute of Biological Products and Beijing Institute of Biological Products, showed an efficacy of 72.8 and 78.1 percent respectively against symptomatic COVID-19 cases, with rare serious adverse effects reported and it is the world’s first published phase-3 study results of inactivated COVID-19 vaccines.

China promised an additional 3 billion dollars in international aid over the next three years to support pandemic response and economic and social recovery in other developing countries at the Global Health Summit on May 21.

Chinese vaccines are now part of the immunization campaigns in many developing countries and have gained more recognition worldwide.

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.